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ABSTRACT 
Coeliac disease is hallmarked by an abnormal immune reaction against ingested wheat-, rye- and barley-
derived gluten and the presence of transglutaminase 2 (TG2)-targeted autoantibodies. The small-bowel 
mucosal damage characteristic of the disorder develops gradually from normal villus morphology to 
inflammation and finally to villus atrophy with crypt hyperplasia. Patients with early-stage coeliac disease 
have TG2-autoantibodies present in serum and small-intestinal mucosa and they may already suffer from 
abdominal symptoms before the development of villus atrophy. Previously we have shown that intraperitoneal 
injections of coeliac patient-derived sera or purified immunoglobulin fraction into mice induce a condition 
mimicking early-stage coeliac disease. In the current study, we sought to establish whether recombinantly 
produced patient-derived TG2-targeted autoantibodies are by themselves sufficient for the development of 
such an experimentally induced condition in immune-compromised mice. Interestingly, mice injected with 
coeliac patient TG2-antibodies had altered small-intestinal mucosal morphology, increased lamina propria 
cellular infiltration and disease-specific autoantibodies deposited in the small bowel, but did not evince clinical 
features of the disease. Thus, coeliac patient-derived TG2-specific autoantibodies seem to be sufficient for the 
induction of subtle small-bowel mucosal alterations in mice, but the development of clinical features probably 
requires additional factors such as other antibody populations relevant in coeliac disease.  
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INTRODUCTION 
Coeliac disease is a common autoimmune disorder which occurs in a subset of genetically predisposed 
individuals in response to ingestion of gluten-containing wheat, rye and barley. Patients present with a wide 
constellation of symptoms and clinical manifestations, of which the most typical are chronic diarrhoea, 
malabsorption and failure to thrive in childhood (Kaukinen et al. 2010). A characteristic feature of the disease 
is the presence of disease-specific antibodies in patient serum. These circulating antibodies target both gluten-
derived deamidated gliadin peptides (DGP) (Kaukinen et al. 2007) and a self-antigen, transglutaminase 2 
(TG2) (Dieterich et al. 1997). Evidence shows that the TG2-autoantibodies are produced in the small-intestinal 
mucosa (Marzari et al. 2001; Picarelli et al. 1996), where they can bind TG2 present in the basement membrane 
and around blood vessels and form deposits characteristic of the disease (Di Niro et al. 2012; Korponay-Szabó 
et al. 2004; Koskinen et al. 2008; Marzari et al. 2001). The TG2-targeted autoantibodies have been 
demonstrated to mediate a wide spectrum of effects at in vitro, ex vivo and in vivo levels (Caja et al. 2011; 
Caputo et al. 2013; Kalliokoski et al. 2013; Martucciello et al. 2012; Paolella et al. 2013), but their contribution 
to the disease pathogenesis remains as yet incompletely understood. 
In untreated coeliac disease, the damaged small-bowel mucosa is hallmarked by villous atrophy and crypt 
hyperplasia as well as the activation of both adaptive and innate immune responses. The adaptive immune 
component encompasses a pro-inflammatory response characterized by secretion of cytokines such as 
interferon (IFN)-γ, interleukin (IL)-1β and IL-6 (Lahat et al. 1999; Nilsen et al. 1995; Przemioslo et al. 1994). 
In contrast, a key player in the innate immune response is cytokine IL-15, which contributes to disease 
development for instance by promoting small-bowel mucosal epithelial damage (Kim et al. 2015). As a result, 
the impaired epithelium is no longer viable as a proper barrier, which leads to increased intestinal permeability 
in coeliac disease (van Elburg et al. 1993; Reims et al. 2002; Schulzke et al. 1998). 
The small-bowel mucosal damage in coeliac disease evolves gradually and may take years or even decades to 
develop (Lähdeaho et al. 2005; Mäki et al. 1990; Marsh 1992). However, it is known that many signs of the 
disease are already present in the early phases of the disease, prior to the appearance of villous atrophy. Patients 
with early developing coeliac disease still have a morphologically normal small-intestinal mucosal villus 
structure, but they may already have autoantibodies in their circulation and TG2-autoantibody deposits and an 
increased number of inflammatory cells in their small-bowel mucosa (Korponay-Szabó et al. 2004; Salmi et 
al. 2006). Moreover, these patients may suffer from various gastrointestinal symptoms, for example diarrhoea 
and abdominal pain, before development of villous atrophy (Kaukinen et al. 2001; Kurppa et al. 2009). 
Recently, we demonstrated that injection of coeliac patient sera or purified serum immunoglobulins into 
immune-compromised mice leads to a condition with characteristics of early developing coeliac disease 
(Kalliokoski et al. 2015). The mice had intestinal inflammation and TG2-autoantibodies in their sera and small-
bowel mucosa. Moreover, a subset of the animals failed to gain weight and evinced signs of mild diarrhoea. In 
the current study, we further investigated the effects of the coeliac disease patient antibodies, and addressed 
the question whether patient-derived TG2-targeted autoantibodies are by themselves able to induce the early 
developing coeliac disease–like condition in mice and factors associated with the alterations. 
 
MATERIALS AND METHODS 
Production and purification of monoclonal miniantibodies 
The following IgG-class recombinant monoclonal miniantibodies were used in the study: coeliac patient anti-
TG2-specific monoclonal antibody clone 4.1 (referred to in the article as CD Mab) and an irrelevant control 
antibody against a Helicobacter pylori antigen (referred to as non-CD Mab). They were produced in scFv-Fc 
format in Chinese hamster ovary cells (CHO-S) transfected with pUCOE vector as previously described 
(Boscolo et al. 2012).  
Miniantibodies were isolated from the medium with an HiTrap Protein A HP column (Bed Volume 5 ml, GE 
Healthcare Europe, GmbH, Freiburg, Germany). Prior to isolation the medium was diluted to binding buffer 
(20 mM sodium phosphate buffer, pH 7). Unbound proteins were removed by washing with binding buffer 
followed by elution of miniantibody with 0.1 M citric acid (pH 3) into tubes containing neutralization buffer 
(1 M Tris, pH 9). Elution fractions containing monoclonal miniantibody were pooled and immediately dialysed 
against phosphate-buffered saline (PBS) (pH 7.5). Protein concentrations were determined by measuring 
absorbance at a wavelength of 280 nm. Thereafter, concentrations of miniantibodies were calculated using the 
molar attenuation coefficient (ε = 135150 L⋅mol−1⋅cm−1) and molecular weight (MW = 57101.2 g/mol) for the 
protein. 
An indirect immunofluorescence method was used to determine IgG-class coeliac disease-specific 
endomysium antibody (EmA) titres in the miniantibody preparations. Human umbilical cord from a premature 
baby was used as substrate, and a serum dilution of 1:10 or more was considered positive (Korponay-Szabó et 
al. 2003). Positive antibody preparations were further diluted 1:50, 1:100, 1:200, 1:500, 1:1000, 1:2000, 
1:4000, 1:8000, 1:12000 and 1:16000. An enzyme-linked immunosorbent assay (ELISA) method using human 
recombinant TG2 as antigen was used to measure IgG-class antibodies against TG2 (cut-off 3 U/ml, Celikey®, 
Phadia GmbH, Freiburg, Germany) in the miniantibody preparations.  
 
Experimental animals, housing and husbandry 
Twenty-five female Hsd:Athymic Nude-Foxn1nu mice (Envigo, Gannat, France) 6 weeks of age were used in 
the study. All animals were kept in semi-barrier conditions in the facilities of the Central Animal Laboratory, 
University of Turku, Finland. All mice were acclimatized at least two weeks prior to the commencement of 
the study. After the acclimatization period, all animals were randomly assigned to single cages. At the 
beginning of the experiments, each animal was housed in top-filtered stainless steel type II cages (36.5 x 20.7 
x 14 cm) with solid base, with nesting material and an igloo as environmental enrichment and Aspen chips as 
bedding (Tapvei Ltd, Paekna, Estonia). The temperature range in the animal room was 19-22 °C, the relative 
humidity 42 to 60%, and artificial illumination followed a 12-h light/dark cycle (lights on at 6 am). The mice 
had ad libitum access to a standard gluten-containing mouse chow (Special Diet Services, Witham, Essex, UK) 
and were provided free access to tap water in polycarbonate bottles. The mice were considered specific-
pathogen-free (including free of mouse norovirus and Helicobacter species) based on the results of 
microbiological screening in the colony, and during the course of the experiments their physical condition was 
assessed daily on the basis of gross clinical examination. The mice were cared for and used in accordance with 
the current European (Directive 2010/63/EU) and Finnish (Act 2013/497 and Decree 2013/564) legislation on 
the protection of animals used for scientific purposes. The animal experiments were conducted as appoved by 
the National Ethics Committee for Animal Experiments in Finland (license numbers ESAVI-2010-06223/Ym-
23, ESAVI/4279/04.10.07/2013 and ESAVI/781/04.10.07/2015). 
 
Study design and experimental procedures 
In the CD Mab preparations (protein concentration about 2 mg/ml), the IgG-class EmA titres were 1:8000 or 
higher, and IgG-class TG2-antibody levels above 100 U/ml, whereas the non-CD Mab was negative for both 
types of coeliac autoantibodies. The overall protein concentration of non-CD Mab was adjusted to the level of 
CD Mab. The mice were injected with CD Mab (n=10 mice), irrelevant non-CD Mab (n=10 mice) or sterile 
PBS (n=5 mice). Single daily intraperitoneal injections of antibodies or PBS (10 ml/kg mouse) were performed 
for 8 days. The body weights of the animals were recorded daily during the experiment. At the beginning of 
the daily injections, the median weight of CD Mab-receiving mice was 24.7 g (range 21.1-30.2 g), non-CD 
Mab-receiving mice 25.4 g (range 22.0-30.3 g) and PBS-receiving mice 27.1 g (range 23.1-28.1 g). Faecal 
consistency was evaluated daily and graded as normal faeces, mild diarrhoea, moderate diarrhoea and severe 
diarrhoea as previously described (Kalliokoski et al. 2015). 
To measure intestinal permeability, an iohexol test was performed on five mice per group essentially as 
described elsewhere (Frias et al. 2009; Frias et al. 2014). The test was carried out two weeks before initiation 
of antibody or PBS injections and again after completion of the 8-day injections. For iohexol permeability 
testing, 10ml/kg of Omnipaque 300 (647 mg iohexol mg/ml Amersham Health, the Netherlands) was 
administered to the mice by oral gavage, whereafter they were placed in metabolic cages for 24 h for urine 
collection. After recording of total urine volume, the urine samples were collected and stored at ‒20 °C for 
iohexol measurements. 
At the end of the experiment the mice were anaesthetized using isoflurane (Vetflurane 1000 mg/g, Virbac, 
Suffolk, UK), blood collected by cardiac puncture, and sera separated by centrifugation at 1500 x g for 10 
minutes and stored at –70°C. After euthanasia tissue samples from the small bowel, heart, kidney, liver and 
skeletal muscle were collected. The samples were either freshly embedded in optimal cutting temperature 
compound (Tissue-Tek, Miles Inc, Elkhart, IN, USA), frozen in liquid nitrogen, and stored at –70°C, or fixed 
in 10% phosphate-buffered neutral formalin and embedded in paraffin. During the experiment, one mouse 
receiving PBS died on day six after starting the antibody and PBS injections and thus the serum and tissue 
samples from this animal were collected at this time point. 
 
Human antibody measurements from mouse sera 
Total human IgG levels were determined in mouse sera by an Immunoglobulin G ELISA Kit specifically 
recognizing human immunoglobulins (ImmunoDiagnostik, Bensheim, Germany). The assay was performed 
according to the manufacturer’s instructions, and the levels of IgGs were given as mg/ml, based on the 
standards provided in the kit. IgG-class EmA titres and TG2-antibody levels in mouse sera were determined 
as described above. 
 
Laboratory analysis of iohexol in mouse urine 
Iohexol levels in mouse urine were determined using the FIT-GFR Iohexol Kit (BioPAL, Inc., Worcester, MA, 
USA). Urine samples were disregarded in the case of incomplete collection or faecal contamination. Iohexol 
standards from the kit were prepared using BioPAL diluent (0.01 0.03, 0.1, 0.3, 1.0, 3.0, 10.0 μg/ml). The 
urine samples were diluted 1:5000 and the test then carried out according manufacturer’s instructions. The 
absorbance at 450 nm for each sample was recorded by a plate reader (EnSight™ multimote plate reader, 
Kaleido™ Data Acquisition and Analysis software), and data on the standards were fitted to a four-parameter 
logistic function. Finally, the amount of iohexol in mouse urine was calculated as described by Frias and 
colleagues (Frias et al. 2014) as follows: 
𝐼𝑜ℎ𝑒𝑥𝑜𝑙 𝑖𝑛 𝑢𝑟𝑖𝑛𝑒 (%) =
𝑖𝑜ℎ𝑒𝑥𝑜𝑙 𝑖𝑛 𝑢𝑟𝑖𝑛𝑒 (𝑚𝑔) ×  𝑇𝑈𝑉 (𝑚𝑙)
𝑖𝑜ℎ𝑒𝑥𝑜𝑙 𝑔𝑖𝑣𝑒𝑛 𝑜𝑟𝑎𝑙𝑙𝑦 (𝑚𝑔) × 𝑇𝑇𝑆𝑉 (𝑚𝑙)
 × 100   
 TUV, total urine volume; TTSV, total volume of oral solution containing iohexol  
The results are presented as percentage of iohexol in urine. 
 
Immunohistochemistry and small-bowel mucosal morphology 
For immunohistochemical stainings, 3-μm-thick well-oriented sections were cut from paraffin blocks of 
formalin-fixed proximal parts of mouse small intestines. Thereafter, the sections were deparaffinized in xylene 
and rehydrated in descending ethanol series. Antigens were exposed by heat-induced antigen retrieval, and 
endogenous peroxidase activity blocked with 0.3 % H2O2. Non-specific antibody binding sites were blocked 
prior to primary antibody incubations at 4°C overnight. Rabbit anti-mouse antibodies against Ki-67 (1:400, 
Novus Biologicals, LLC, Littleton, CO, USA), and active caspase-3 (1:250, Cell Signalling Technology, 
Danvers, MA, USA), neutrophil elastase (1:1000, Abcam, Cambridge, UK) and F4/80 (1:100, Novus 
Biologicals) were used as primary antibodies. Subsequently, the sections were incubated with biotinylated goat 
anti-rabbit antibody (1:200, Vector Laboratiories Inc, Burlingame, CA, USA), HRP-conjugated swine anti-
rabbit antibody (1:200, Dako Denmark A/S, Glostrup, Denmark), Rabbit-on-Rodent HRP-polymer (Biocare 
Medical, LLC., Concord, CA, USA) or ImmPRESS Reagent (ImmPRESS HRP Anti-Rabbit IgG (Peroxidase) 
Polymer Detection Kit, Vector Laboratories), respectively. Immunodetection was done using ABC solution 
(Vectastain Elite ABC kit, Vector Laboratories) followed by 3-amino-9-ethylcarbazole (AEC) or 3,3'-
diaminobenzidine (DAB). The sections were counterstained with Harris haematoxylin. 
Ki-67-stained small-intestinal sections of mice were used for morphological assessments as previously 
described (Kalliokoski et al. 2015). Villous height, crypt depth and villous height crypt depth ratio (Vh/CrD) 
were determined approximately from 15 measurements per mouse. In addition, total amounts of cells and Ki-
67-positive proliferative cells per mm2 of lamina propria were enumerated by approximately 30 measurements 
per mouse. Active caspase-3-stained sections were analysed for apoptosis with a three-grade scale: no staining, 
single positive cells and continuously stained villous tips. Neutrophil elastase- and F4/80-positive cells were 
counted per mm2 of mouse small-intestinal tissue. 
 
Quantification of epithelial cell subsets by quantitative real-time PCR 
Small-intestinal epithelial cells were isolated from five CD Mab- and five non-CD Mab-injected mice. 
Harvested duodenal fragments were opened longitudinally and washed with cold PBS until the supernatant 
was clear. Tissue was chopped into approximately 5-mm pieces and incubated in 2mM EDTA-phosphate 
buffered saline chelation buffer for 30 minutes rocking at 4C. After removal of EDTA-chelation buffer, tissue 
fragments were vigorously resuspended in PBS and pipetted up and down 20 times in a 10ml pipette. 
Supernatant containing epithelium from villi and crypts was collected, followed by two washes of the tissue, 
and supernatants from the washes were pooled. Total RNA was extracted from isolated small-intestinal 
epithelial cells with TRIzol Reagent (Life Technologies, Carlsbad, CA, USA) according manufacturer’s 
instructions. RNA was converted to cDNA using an iScript Select cDNA Synthesis Kit (Bio-Rad, Hercules, 
CA, USA) and random primers as instructed by the manufacturer. Quantative real-time PCR (qPCR) was 
performed using an Evagreen Ssofast supermix kit (Bio-Rad) according to manufacturer’s instructions. Primer 
sequences are described in supplementary Table 1. The housekeeping gene GAPDH was used as normalization 
control. An average threshold cycle (Ct) value was calculated from three replicate samples per mouse. The 
messenger RNA (mRNA) levels are expressed relative to those of the housekeeping gene in the results. 
 
Small-bowel mucosal TG2-specific IgG deposit staining in mice 
IgG deposits were stained essentially as previously described (Kalliokoski et al. 2015). In brief, frozen  
proximal small-intestinal sections were double-stained for human IgG and TG2 using DyLightTM594-
conjugated goat anti-human IgG antibody (Jackson ImmunoResearch Laboratories, Inc., West Grove, PA, 
USA) and polyclonal rabbit antibody to tissue transglutaminase (Zedira GmbH, Darmstadt, Germany), 
followed by Alexa Fluor 488-conjugated goat anti-rabbit antibody (Molecular Probes, Eugene, OR, USA). 
Fluorescein isothiocyanate-conjugated rabbit antibody against human IgG (Dako Denmark A/S) was used for 
deposit staining in other tissues. The slides were mounted with Vectashield mounting medium containing 
DAPI (Vector Laboratories, Inc.), and images taken with an Olympus BX60 microscope (Olympus Europa 
GmbH, Hamburg, Germany). 
 
Cytokine analysis 
Small-intestinal specimens from five CD Mab-treated and five non-CD Mab-treated mice were cut out of 
frozen Tissue-Tek and weighed. Thereafter, 500 µl of ice-cold H-buffer (150 mM NaCl, 5 mM EDTA, 50 mM 
potassium phosphate, pH 7.4) containing complete protease inhibitor cocktail (Roche Diagnostics, Mannheim, 
Germany) was added per 100 mg of tissue. Tissues were homogenized with Ultra Turrax T8 tissuemizer (IKA 
Labortechnik, Staufen, Germany), supernatants collected after centrifugation at 4°C and total protein 
concentration measured using Bio-Rad CD Protein Assay (Bio-Rad). Supernatants were diluted to 10 mg 
protein/ml with PBS and used in the assay. Protein expression levels of eleven cytokines (IL-1β, IL-3, IL-6, 
IL-15/IL-15R, IL-17A, IL-27, IFN-γ, granulocyte-macrophage colony-stimulating factor (GM-CSF), tumour 
necrosis factor (TNF)-α, epithelial neutrophil activating peptide (ENA-78) and macrophage inflammatory 
protein (MIP)-2) were measured with the Bio-Plex 200 system (Bio-Rad) using a ProcartaPlexTM Multiplex 
Immunoassay (eBioscience, San Diego, CA, USA) in accordance with the manufacturer’s instructions. The 
amounts of the cytokines were calculated based on the standard curves. Values below the detection limit were 
set to zero for statistical analysis. 
 
Statistics 
Statistical analysis was made using statistical analysis software (IBM SPSS Statistics, SPSS Inc., Chicago, IL, 
USA). Data are presented as medians and ranges. Kruskal-Wallis test followed by Mann-Whitney U test were 
used to compare differences between the groups and Wilcoxon test to compare changes within the groups. 
Correlations were studied using Spearman’s correlation test. In the correlation analysis, data on Vh/CrD and 
lamina propria cell infiltration from a previously published study (Kalliokoski et al. 2015) were also included. 
These data include Vh/CrD and lamina propria cell infiltration values from mice injected with coeliac disease 
patient (n=8 mice) or control individual (n=8 mice) sera as well as total serum IgG from coeliac patients (n=5 
mice) or control individuals (n=5 mice), and non-injected mice (n=4). A p-value ≤0.05 being considered 
significant. 
 
RESULTS 
Determination of human antibodies and small-bowel morphology 
To confirm that the intraperitoneal injections of recombinantly produced human CD Mab and non-CD Mab 
into mice were successful, human IgG levels in mouse sera were measured at the end of the experiment. All 
the mice injected with antibodies had human IgG in their circulation. Despite the comparable total protein 
concentrations of the injected antibodies, the mice injected with CD Mab had lower levels of human IgG in 
their sera (median 0.08 mg/ml) than the non-CD Mab-injected mice (median 0.35 mg/ml). All PBS-injected 
mice were negative for human IgG (Table 1). 
Mouse sera were also tested for IgG-class coeliac disease-specific EmA- and TG2-autoantibodies. Notably, all 
mice receiving CD Mab were positive for both autoantibodies, the median levels being 1:1000 and 87 U/ml 
for EmA- and TG2-antibodies, respectively. None of the non-CD Mab- and PBS-injected mice had detectable 
levels of either of these antibodies (Table 1). 
Interestingly, mice receiving CD Mab had significantly lower small-intestinal mucosal villi (median 434 µm, 
range 355-541 µm) than mice injected with non-CD Mab (median 470 µm, range 357-585 µm) or PBS (median 
474 µm, range 382-519 µm) (Fig. 1a). There was no significant difference in crypt depth between CD Mab 
and non-CD Mab injected mice (medians 103 µm and 94 µm, respectively). However, the control mice injected 
with PBS had significantly shorter crypts (median 80 µm) than the mice injected with either CD Mab or non-
CD Mab. (Fig. 1b). Of note, Vh/CrD was significantly lower in mice receiving CD Mab (median 4.41) in 
comparison to those receiving non-CD Mab (median 4.86) or PBS (median 5.33). The difference in Vh/CrD 
between non-CD Mab-treated mice and PBS-treated mice was also statistically significant. (Fig. 1c). 
All mice receiving CD Mab evinced clear human IgG positivity in the small-intestinal mucosa at the basement 
membrane and around blood vessels. Notably, the coeliac patient TG2-targeted miniantibodies localized with 
mouse TG2 at these sites (Table 1). Human IgG-class miniantibody deposits were also detected in heart, 
kidney, liver and skeletal muscle (data not shown). The presence of CD Mab in several mouse tissues could 
account for the lower levels of human IgG observed in the circulation of the mice injected with CD Mab. None 
of the non-CD Mab- or PBS-injected mice exhibited such deposits. 
 
Clinical observations and intestinal permeability 
Weight and faecal consistency were monitored throughout the experiment. At the end of the experiment, 
median weights of CD Mab-, non-CD Mab- and PBS-injected mice were 25.0 g (range 20.4-29.5 g), 25.2 g 
(range 22.6-29.6 g) and 26.0 g (range 21.9-28.0 g), respectively, and thus no significant differences in the 
increment of body weight were found between groups. In addition, within each treatment group, the body 
weights remained fairly constant during the procedure. 
During the entire length of the experiment, the stool consistency of all mice was mostly graded as normal with 
occasional transient mild diarrhoea in some animals.  However, there was no difference in the occurrence of 
such transient mild diarrhoea between the three study groups (data not shown). 
Intestinal permeability in the mice was studied by determining the percentage of orally administered iohexol 
in mouse urine. Before antibody injections, the median percentage of iohexol in the CD Mab-group was 1.00% 
(range 0.15-2.22%), non-CD Mab-group 0.15% (range 0.14-8.64%) and PBS-group 0.31% (range 0.04-
1.39%). After the 8-day antibody- or PBS-injection period, no significant increase in the percentage of iohexol 
in urine was observed in any of the groups, the median percentages being 0.33% (range 0.14-4.31%), 0.23% 
(range 0.13-2.67%) and 0.43% (range 0.15-0.96%) in CD Mab-, non-CD Mab- and PBS-injected mice, 
respectively. 
 
Epithelial cell subsets and apoptosis 
To assess whether the observed changes in the small-intestinal mucosal morphology of CD Mab-injected mice 
could be due to altered differentiation of epithelial cells, we evaluated the mRNA expression of distinct 
intestinal epithelial cell differentiation markers by qPCR. The mRNA expression level of the enterocyte marker 
ALP1, the enteroendocrine marker CHGA, the Paneth cell marker LYZ1, the goblet cell marker MUC2 and 
stem cell marker LGR5 were similar in CD Mab and non-CD Mab injected mice (Supplementary Fig. 1). 
In the case of apoptosis, it was observed that all mice evinced active caspase-3 positivity in single epithelial 
cells located mostly in the villous tips. In the lamina propria only rare caspase-3 positive cells were detected. 
However, no differences in the level of apoptosis were observed between CD Mab and the control groups 
(Supplementary Fig. 2). 
 
Lamina propria cellular infiltration 
In order to quantify mucosal lamina propria cellular infiltration, we enumerated the total number of cells and 
Ki-67-expressing proliferative cells per mm2 of lamina propria in mouse small intestines. The total number of 
lamina propria cells was significantly higher in mice injected with CD Mab (median 9553, range 7083-12145 
cells) when compared to non-CD Mab- (median 7344 cells, range 5841-8229 cells) or PBS-injected mice 
(median 7042 cells, range 6473-7917 cells) (Fig. 2a). A parallel finding was observed in the number of Ki-67 
positive proliferating lamina propria cells, where the amounts were 990 (range 130-1583 cells), 505 (range 
208-833 cells) and 229 cells (range 167-458 cells) in CD Mab-, non-CD Mab- and PBS-injected animals, 
respectively (Fig. 2b). The values in the CD Mab group were statistically different from those in both controls 
groups.  The difference between the non-CD Mab and PBS groups was also statistically significant. 
Notably, a significant negative correlation was found between Vh/CrD and number of proliferative cells in the 
lamina propria (P=0.007) (Fig. 3a). As we had the Vh/CrD data and the number of lamina propria cells 
available from our previous experiments, where we injected either coeliac or control serum or total serum IgG 
from coeliac patients or controls to mice (Kalliokoski et al. 2015), we performed the correlation analysis also 
taking this data set into consideration. In this larger data set, a negative correlation was found between Vh/CrD 
and number of proliferative cells in the lamina propria (P≤0.001) (Fig. 3b) and also between Vh/CrD and total 
number of cells in the lamina propria (P≤0.001) (Fig. 3c). 
 
 
 
Cytokine expression levels in small intestines of mice 
The expressions of 11 cytokines were determined in small-intestinal tissue homogenates from mice receiving 
CD Mab or non-CD Mab. Protein levels of IL-3, IFN-γ, IL-17A and GM-CSF were below the detection limit 
range in all mice and thus excluded from further analysis. IL-1β, IL-6, IL-15, IL-27, ENA-78, MIP-2 and TNF-
α were chosen for further evaluation, but no statistically significant differences were found in the expression 
levels of these cytokines between CD Mab-treated and non-CD Mab-treated mice. However, three out of five 
CD Mab-injected mice had detectable levels of IL-27 (median 4.97 pg/ml in the samples above detection limit), 
while in all five non-CD Mab injected mice the level of IL-27 was below the detection limit. In addition, four 
out of five CD Mab-injected mice had measurable levels of intestinal TNF-α (median 4.2 pg/ml in the samples 
above detection limit), in contrast to only one non-CD Mab-injected mice (3.9 pg/ml). 
The amount of intestinal IL-27 correlated significantly with the number of Ki-67-positive proliferating cells in 
the lamina propria (P=0.042), and a similar trend was observed between IL-27 and total amount of infiltrative 
cells in the lamina propria (P=0.056) (Table 2). In addition, TNF-α levels correlated with both the Ki-67-
positive cells in the lamina propria and the total amount of infiltrative cells (P=0.041 and P=0.036, 
respectively). A positive correlation was also found between the levels of TNF-α and IL-27 (P=0.018) and the 
levels of TNF-α and IL-1β (P=0.041) (Table 2). 
 
DISCUSSION 
In this study, we demonstrated that the administration of coeliac disease-specific TG2-targeted recombinantly 
produced miniantibodies into athymic mice induces an alteration in the small-intestinal mucosal morphology 
coupled with increased cellular infiltration in the lamina propria. CD Mab-injected mice also evinced coeliac 
patient autoantibodies in the serum and small-bowel mucosa, where they co-localized with TG2. Thus, these 
results are parallel to those in our previous study with coeliac patients’ sera and immunoglobulin injections 
(Kalliokoski et al. 2015). However, the injection of CD Mab did not affect the occurrence of diarrhoea, 
intestinal permeability or increment of body weight. 
According to our results epithelial cell apoptosis was not increased in the presence of CD Mab, thus paralleling 
earlier findings (Barone et al. 2007). In addition, CD Mab injections did not affect the proportions of different 
intestinal epithelial cell lineages, which together with unaffected apoptosis might thus partly account for the 
unchanged intestinal permeability in the current study. Interestingly, decreased expression of distinct 
junctional proteins (Rauhavirta et al. 2014) and increased permeability (Smecuol et al. 2005) have been 
reported in gluten-sensitive individuals with normal small-intestinal mucosal morphology. Therefore, other 
factors along with TG2-targeted autoantibodies are likely needed for the induction of epithelial permeability 
at the early phases of coeliac disease development. On the other hand, the injections of CD Mab to mice 
induced elongation of crypts suggesting that crypt epithelial cell proliferation could be increased. Indeed, a 
previous study shows that antibodies against TG2 are able to induce the entry of epithelial cells into S-phase 
(Barone et al. 2007). However, in the CD Mab-injected mice, changes in both crypt depth and also villous 
height in mice were milder than observed in untreated overt coeliac patients present with considerable villous 
atrophy and large-scale crypt hyperplasia, and there might be several reasons for that. For instance, the mice 
used in the present and previous (Kalliokoski et al. 2015) study lack T-cells and also the correct major 
histocompatibility complex (MHC) molecules, which both are relevant for the adaptive immune response in 
the coeliac disease pathogenesis (du Pré and Sollid 2015). In addition, innate immune activation (Kim et al. 
2015), structural changes in epithelial cell layer (Hüe et al. 2004) and epithelial stress (Setty et al. 2015) are 
involved in the development of the small-bowel mucosal damage in coeliac patients. Therefore, these factors 
along with coeliac disease antibodies might be necessary for the development of both total villous atrophy and 
increased permeability. 
In contrast to our previous study, the administration of TG2-targeted autoantibody into mice did not led to a 
significant delay in weight gain. Surprisingly, the mouse body weight in the current study actually remained 
fairly constant throughout the study period in all groups. This was presumably because the weights at the 
beginning of the injection period had for some reason already reached that of adults, as reported by the 
company the animals were purchased from. Furthermore, in the current study there was no difference in the 
occurrence of mild transient diarrhoea between groups, in contrast to the previous study (Kalliokoski et al. 
2015). Several factors might account for this difference. Firstly, the current study was performed by injecting 
TG2-specific autoantibodies targeting a single previously identified classical coeliac epitope, while 
autoantibodies against an additional three major TG2-epitopes also exist in coeliac patients (Iversen et al. 2013; 
Simon-Vecsei et al. 2012). Secondly, even though not reported, DGP-antibodies were found in the majority of 
the mice injected with coeliac patient-derived sera or immunoglobulins in the previous study, and also other 
antibody populations in addition to the TG2-antibodies were very likely present in the injections. Thus, we 
propose that a combined action of TG2-autoantibodies targeting different epitopes and/or other antibody 
populations such as DGP-antibodies might be required for the development of diarrhoea in the mice. However, 
it must be noted that also patients presenting with early developing coeliac disease do not always present with 
gastrointestinal symptoms, including diarrhoea (Salmi et al. 2006; Kurppa et al. 2009). 
To our knowledge, only two previous studies have assessed the effects of autoimmunity against TG2 using 
murine models, and neither reports any signs of diarrhoea or effects on weight gain (Di Niro et al. 2008; Freitag 
et al. 2004). The first study by Freitag and co-workers included the induction of a humoral response against 
TG2 by immunizing mice with exogenous TG2 (Freitag et al. 2004). Although high levels of anti-TG2 
antibodies in mouse sera were detected, no histological changes in the small intestine were observed, in 
contrast to our study.  Even though not reported in the article, it is very likely that the epitopes of the murine 
TG2-autoantibodies deviate considerably from those of the coeliac patients, thus providing a possible 
explanation for the differences in the findings. In the second study, Di Niro and colleagues expressed TG2-
miniantibodies in immune competent mice by means of adeno-associated virus vectors (Di Niro et al. 2008). 
Regardless of using a coeliac patient-derived single-chain TG2-miniantibody similarly to the one used in our 
study, they observed no morphological alterations in small-bowel mucosa despite the presence of the 
antibodies in serum. On the other hand, in their study, a strong anti-idiotypic response was apparent in the 
mice, which may explain the lack of small-bowel mucosal morphological changes. Interestingly, the idiotypic 
antibodies observed in Di Niro’s study competed with TG2 for miniantibody binding, and might thus have 
prevented the formation of deposits in most tissues, including the small intestine. It is thus conceivable that 
autoantibodies deposited in the small intestine might be one factor inducing decreased Vh/CrD. 
Although as discussed above, intestinal epithelial cell alterations likely do not contribute to the alteration in 
mucosal morphology in CD Mab-injected mice, our results suggest the autoantibodies deposited to the small 
bowel mucosa might play a role. One plausible mechanism is the activation of the complement system, 
although our data does not support this conception (data not shown). In addition, an increased density of both 
all infiltrative cells and the proliferating infiltrative cells was present in CD Mab-injected mice compared to 
controls. This increased density of infiltrative cells in the lamina propria of the mice injected with CD Mab, 
however, might not be attributable to neutrophils or macrophages. The number of neutrophil elastase-positive 
cells was very low in all animals and no differences between groups were observed (data not shown). 
Macrophages were abundantly present in the lamina propria, but their amount did not differ between study 
groups either (data not shown). Nonetheless, there was a significant negative correlation between Vh/CrD and 
number of Ki-67-positive proliferating cells in the lamina propria. In the larger data set combining mice from 
our previous serum and total IgG experiments, both infiltration parameters, Ki-67-positive cells and total 
number of cells in the lamina propria, correlated negatively with Vh/CrD. Our results would thus indicate that 
the infiltrative cells in the lamina propria could be involved in the process of mucosal deterioration. Further 
research is needed to determine which cell types are responsible for the increased infiltration in these mice.  
We showed that lamina propria infiltration parameters also correlated with the levels of IL-27 and TNF-α. 
Although the expression levels of these cytokines in CD Mab-injected mice did not differ significantly from 
those in control mice, the observed trend towards increased levels of IL-27 and TNF-α in mice receiving CD 
Mab could have reached statistical significance by increasing the number of animals. Our finding of IL-27 
protein in the small intestine of the CD Mab-injected mice is intriguing, as in active coeliac disease patients’ 
biopsy specimens the expression of IL-27 mRNA has been reported to be increased (Garrote et al. 2008). With 
regard to TNF-α, numerous studies report elevated levels of TNF-α in coeliac disease patients (Cataldo et al. 
2003; Kontakou et al. 1995; Manavalan et al. 2010; Przemioslo et al. 1994; Westerholm-Ormio et al. 2002). 
However, the entire small-intestinal cytokine profile of the mice did not resemble that observed in coeliac 
disease patients (Garrote et al. 2008; Lahat et al. 1999; Iacomino et al. 2016). For instance, no differences in 
the levels of IL-15, the innate immunity cytokine overexpressed in coeliac patients’ small-intestinal epithelia 
and lamina propria (Di Sabatino et al. 2006; Iacomino et al. 2016; Maiuri et al. 2000; Mention et al. 2003), 
were observed between CD Mab- and control group mice. In addition, the levels of other pro-inflammatory 
cytokines such as IFN-γ, IL-1β and IL-6 have been increased in active coeliac patients in several studies 
(Fornari et al. 1998; Kontakou et al. 1994; Manavalan et al. 2010; Nilsen et al. 1998), but no significant increase 
was found in our CD Mab-treated mice compared to controls. This difference in the cytokine profile between 
coeliac patients and CD Mab-injected mice is not surprising, since the mice we used in the study were immune-
compromised T-cell deficient mice and thus unable to mount the cytokine response characteristic of T-cell-
mediated adaptive immune activation. 
In summary, we observed that injections of coeliac disease-specific miniantibodies targeting major TG2 
epitope into mice induced a condition resembling early phase disease in coeliac patients, encompassing slight 
albeit significant morphological alterations, increased cellular infiltration and TG2-antibody deposits along the 
basement membrane and blood vessels in the small intestines of the mice. The small-bowel histological 
changes occurred in conjunction with autoantibody deposits, lamina propria cellular infiltration and IL-27 and 
TNF- α, rendering those possible contributors to the process. However, the results suggest that the development 
of clinical features such as diarrhoea requires TG2-antibodies targeting other epitopes, entirely other antibody 
populations and/or longer exposure to the antibodies.  
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TABLES 
 
Table 1 Human IgG-class antibody levels in mouse sera and the presence of miniantibody deposits in the small 
bowel of mice.  
 
CD Mab-injected mice 
(n=10) 
Non-CD Mab-
injected mice 
(n=10) 
PBS-injected 
mice (n=5) 
Human total IgG (mg/ml), 
median (range) 
0.08 (0.03-0.28) 0.35 (0.11-0.62) neg 
EmA-G titre, median (range) 1:1000 (1:200, 1:8000) neg neg 
TG2-G (U/ml), median (range) 87 (60.4, >100) neg neg 
Human anti-TG2-antibody 
deposits in small bowel (% of 
mice) 
100 0 0 
For the serum EmA-G results, a serum dilution of 1:≥10 was considered positive; for TG2-G results, ≥3 
U/ml was considered positive; CD Mab, coeliac patient-derived anti-TG2 miniantibody; non-CD Mab, 
control antibody; EMA-G, IgG-class endomysium antibody; TG2-G, IgG-class transglutaminase2 antibody; 
neg, negative; TG2, transglutaminase 2 
 
 
Table 2 Correlations between cytokine levels and lamina propria infiltration in the mice treated with TG2-
targeted miniantibodies (CD Mab, n=5) or control miniantibodies (non-CD Mab, n=5). Correlation coefficients 
(R) were defined by Spearman’s correlation and P values lower than 0.05 were considered statistically 
significant. 
 IL-27 TNF- α 
 R P value R P value 
Total amount of cells/mm2 
in lamina propria 
0.619 0.056 0.666 0.036 
Ki-67-positive cells/ mm2 
in lamina propria 
0.625 0.042 0.653 0.041 
IL-27 - - 0.724 0.018 
IL-1β 0.515 0.128 0.653 0.041 
IL-27, interleukin-27; IL-1β; interleukin-1β; TNF-α, tumour necrosis factor-α 
  
FIGURE CAPTIONS 
Fig. 1 Small-bowel mucosal morphology of mice. Villous heights (a) and crypt depths (b) were measured and 
villous height crypt depth ratio (Vh/CrD) calculated (c). Each dot represents the median value for one mouse 
calculated from approximately 15 measurements, and black lines indicate the median values of each group. 
Panel d shows representative images of small intestines from coeliac disease-specific anti-TG2-antibody (CD 
Mab)-, control antibody (non-CD Mab)- and PBS-injected mice, respectively. P values lower than 0.05 were 
considered statistically significant and only significant P values are reported in the figure. Scale bar = 50µm 
Fig. 2 Lamina propria infiltration in the mice. Total amount of cells per mm2 of lamina propria (a) and Ki-67-
positive proliferating cells per mm2 of lamina propria (b) were counted in coeliac disease-specific anti-TG2-
antibody (CD Mab)-, control antibody (non-CD Mab)- and PBS-injected mice. Each dot represents the median 
value for one mouse calculated from approximately 30 measurements, and black lines indicate the median 
values of each group. P values lower than 0.05 were considered statistically significant and only significant P 
values are reported in the figure 
Fig. 3 Correlations between villous height crypt depth ratio (Vh/Crd) and lamina propria infiltration. Panel a 
shows the correlation (R, correlation coefficient) between Vh/Crd and number of proliferative Ki-67-positive 
cells per mm2 of lamina propria in mice injected with coeliac (CD Mab) or control antibody (non-CD Mab) or 
PBS. Panels b and c present correlations between Vh/Crd and number of proliferative Ki-67-positive cells or 
total amount of cells per mm2 of lamina propria, respectively. In b and c data from our previous study 
(Kalliokoski et al. 2015) are included. These data represent results from 8- and 27-day experiments with coeliac 
or control serum (CD or non-CD serum, respectively) injections and the 8-day experiment with coeliac or 
control total IgG (CD or non-CD IgG, respectively) injections. Results also include non-injected mice from 
serum and total IgG experiments. P values lower than 0.05 were considered statistically significant  
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Supplementary table 1. List of quantitative real-time PCR oligos used in this study  
Oligonucleotide Species Sequence (5' to 3')  
Gapdh_fwd Mm TGTGTCCGTCGTGGATCTGA  
Gapdh_rev Mm CCTGCTTCACCACCTTCTTGA 
Lgr5_fwd Mm GACAATGCTCTCACAGACGTCC  
Lgr5_rev Mm CAGGGAGTGGATTCTATTATTATGGAG 
Alpi_fwd Mm CCACAAGGCTTCTACCTCTTTGTAG  
Alpi_rev Mm CGGGTGTAGGATTTGTCATCTAGG 
Lyz_fwd Mm GGAATGGATGGCTACCGTGG  
Lyz_rev Mm CACAGGCATTCTTAGATCTTGGG 
Chga_fwd Mm GTGCGTCCTGGAAGTCATCTCC  
Chga_rev Mm GAGAGCCAGGTCTTGAAGTTCC 
Muc2_fwd Mm GGAACCGGGAAGATGCACTC  
Muc2_rev Mm GTCAGCAGCCTCTCACATTCG 
  
Supplementary Fig. 1 Messenger RNA (mRNA) expression of distinct intestinal epithelial cell differentiation 
markers evaluated by quantitative real-time PCR. The levels of the enterocyte marker ALP1, the 
enteroendocrine marker CHGA, the Paneth cell marker LYZ1, the goblet cell marker MUC2 and stem cell 
marker LGR5 are shown. Each dot represents the median value for one mouse calculated from three replicate 
samples and black lines show median values per group. P values lower than 0.05 were considered statistically 
significant, but no significant differences were found between coeliac (CD Mab)- and control antibody (non-
CD Mab)-injected mice 
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Supplementary Fig. 2 Epithelial cell apoptosis was determined by active caspase-3 staining. 
Representative pictures of a) coeliac antibody (CD Mab)- and b) control antibody (non-CD Mab)-
injected mice show single cell positivity mainly at the tips of villi. Higher magnification images (scale 
bar=50µm) show the area marked in the lower magnification images (scale bar=100 µm) 
 
 
 
 
